Shenzhen New Industries Biomedical Engineering Co., Ltd. announced on August 24, 2026, that its Angiotensin-Converting Enzyme Assay Kit (FAPGG Substrate Method) has obtained a Medical Device Registration Certificate issued by the Guangdong Medical Products Administration. The product is registered as Class II, with registration certificate number Yue Xie Zhu Zhun 20262400924, valid from August 19, 2026, to August 18, 2031. It is used for the in vitro quantitative determination of angiotensin-converting enzyme activity in human serum or plasma, and is clinically indicated for drug monitoring in hypertension and auxiliary diagnosis of sarcoidosis. The company stated that this product enriches the hypertension category within its biochemical testing portfolio and will not have a significant impact on recent production, operations, or financial performance.
Shenzhen New Industries BiomedicalObtained medical device registration for new assay kit, expanding product portfolio.
